Latest valproic acid Stories
REHOVOT, Israel, May 31, 2011 /PRNewswire-FirstCall/ -- D-Pharm Ltd. (TASE: DPRM) announced today that it has entered into a licensing and co-development agreement with Jiangsu NHWA Pharmaceutical Co., Ltd.(NHWA) to commercialize DP-VPA for epilepsy in the People's Republic of China.
The law firm of Atkins & Markoff, a team of Oklahoma defective drug attorneys, hereby announces that the firm is reviewing claims free of charge regarding Depakote birth defects along with a full Depakote resource at http://www.atkinsandmarkoff.com.
RESEARCH TRIANGLE PARK, N.C., April 25, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today that the U.S.
Anticonvulsant medications such as Depakote are being found to possibly cause birth defects according to recent studies.
Researchers at the University of Groningen, in the Netherlands, have uncovered that exposure to Valproic acid in fetuses can lead to severe birth defects. Valproic acid is a common ingredient in anticonvulsant drugs such as Depakote.
As lawsuits against the makers of the epilepsy drug Depakote begin to surface in the United States, Depakote lawyers begin to consult with families of birth defect victims about possible Depakote lawsuits.
Most anti-epileptic drugs are associated with an increased risk of non-traumatic fracture in individuals 50 years of age and older.
The prescription drug Depakote is currently the most prescribed branded treatment for patients with mania associated with bipolar disorder as well as for the treatment of epilepsy.
The US Food and Drug Administration has issued a warning to health care professionals and patients about the potential increased risk of birth injuries and birth defects when valproate sodium and related products (e.g. Depacon, Depakote or Stavzor) are used by mothers during pregnancy.
Doctors treating female epilepsy patients have to take account of the specific hormonal situation in women.
- The word or words serving to define another word or expression, as in a dictionary entry.